{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:20:52Z","timestamp":1774372852432,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05375-6","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T07:58:38Z","timestamp":1733126318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of Genitourinary Rhabdomyosarcoma in Phase 3 clinical trials"],"prefix":"10.1007","volume":"43","author":[{"given":"Timothy","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor C.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8987","authenticated-orcid":false,"given":"Kamil","family":"Malshy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Doersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"5375_CR1","doi-asserted-by":"publisher","unstructured":"Castle JT, Levy BE, Allison DB, Rodeberg DA, Rellinger EJ (2023) Pediatric Rhabdomyosarcomas of the Genitourinary Tract., Cancers (Basel). vol. 15, no. 10, May https:\/\/doi.org\/10.3390\/cancers15102864","DOI":"10.3390\/cancers15102864"},{"key":"5375_CR2","doi-asserted-by":"publisher","unstructured":"Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL (Aug. 2014) Declining childhood and adolescent cancer mortality. Cancer 120(16):2497\u20132506. https:\/\/doi.org\/10.1002\/cncr.28748","DOI":"10.1002\/cncr.28748"},{"key":"5375_CR3","doi-asserted-by":"publisher","unstructured":"Williams RF, Fernandez-Pineda I, Gosain A (Oct. 2016) Pediatr Sarcomas Surg Clin North Am 96(5):1107\u20131125. https:\/\/doi.org\/10.1016\/j.suc.2016.05.012","DOI":"10.1016\/j.suc.2016.05.012"},{"key":"5375_CR4","doi-asserted-by":"crossref","unstructured":"Maurer HM et al (Jan. 1988) The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61(2):209\u2013220. https:\/\/doi.org\/10.1002\/1097-0142(19880115)61:2%3C;209::aid-cncr2820610202%3E;3.0.co;2-l","DOI":"10.1002\/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L"},{"key":"5375_CR5","doi-asserted-by":"publisher","unstructured":"Rodeberg DA et al (2011) Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder\/prostate: combined results from the Children\u2019s Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of. Int. J. cancer. vol. 128, no. 5, pp. 1232\u20131239, https:\/\/doi.org\/10.1002\/ijc.25444","DOI":"10.1002\/ijc.25444"},{"key":"5375_CR6","doi-asserted-by":"publisher","unstructured":"Haduong JH et al (2022) Apr., An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children\u2019s Oncology Group clinical trials. Pediatr. Blood Cancer. vol. 69, no. 4, p. e29511, https:\/\/doi.org\/10.1002\/pbc.29511","DOI":"10.1002\/pbc.29511"},{"key":"5375_CR7","doi-asserted-by":"publisher","unstructured":"Bortnick E, Stock J, Ferrer F (2020) Genito-urinary rhabdomyosarcoma-challenges and controversies for the urologist. Translational andrology and urology. vol. 9, no. 5. China, pp. 2422\u20132429, Oct. https:\/\/doi.org\/10.21037\/tau-20-511","DOI":"10.21037\/tau-20-511"},{"key":"5375_CR8","doi-asserted-by":"publisher","unstructured":"Gartrell J, Pappo A (2020) Recent advances in understanding and managing pediatric rhabdomyosarcoma. F1000Research 9. https:\/\/doi.org\/10.12688\/f1000research.22451.1","DOI":"10.12688\/f1000research.22451.1"},{"key":"5375_CR9","doi-asserted-by":"publisher","unstructured":"Zarrabi A et al (Nov. 2023) Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies. Cancers (Basel) 15(21). https:\/\/doi.org\/10.3390\/cancers15215269","DOI":"10.3390\/cancers15215269"},{"key":"5375_CR10","doi-asserted-by":"publisher","unstructured":"Selfe J et al (Jul. 2017) Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: retrospective analyses of patients on UK trials. Pediatr Blood Cancer 64(7). https:\/\/doi.org\/10.1002\/pbc.26386","DOI":"10.1002\/pbc.26386"},{"key":"5375_CR11","doi-asserted-by":"publisher","unstructured":"Hibbitts E et al (2019) Oct., Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children\u2019s Oncology Group. Cancer Med. vol. 8, no. 14, pp. 6437\u20136448, https:\/\/doi.org\/10.1002\/cam4.2504","DOI":"10.1002\/cam4.2504"},{"key":"5375_CR12","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3332\/ecancer.2022.1356","volume":"16","author":"S de Campos Vieira","year":"2022","unstructured":"de Campos Vieira S (2022) International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice guidelines. Ecancermedicalscience 16:1356. https:\/\/doi.org\/10.3332\/ecancer.2022.1356","journal-title":"Ecancermedicalscience"},{"key":"5375_CR13","unstructured":"Children\u2019s Oncology Group Accessed: Aug. 08, 2024. [Online]. Available: https:\/\/www.childrensoncologygroup.org\/about"},{"key":"5375_CR14","unstructured":"Children\u2019s Oncology Group, \u201cVincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma.\u201d Accessed: Aug. 08, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00075582?term=NCT00075582%26rank=1"},{"key":"5375_CR15","unstructured":"Children\u2019s Oncology Group, \u201cCombination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma.\u201d Accessed: Aug. 08, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00354835?term=NCT00354835%26rank=1"},{"key":"5375_CR16","unstructured":"Children\u2019s Oncology Group, \u201cHigh-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma.\u201d Accessed: Aug. 08, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT00354744?term=NCT00354744%26rank=1"},{"key":"5375_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13578-019-0286-y","volume":"9","author":"JG Kiang","year":"2019","unstructured":"Kiang JG, Olabisi AO (2019) Radiation: a poly-traumatic hit leading to multi-organ injury. Cell Biosci 9:25. https:\/\/doi.org\/10.1186\/s13578-019-0286-y","journal-title":"Cell Biosci"},{"issue":"5","key":"5375_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/0360-3016(95)02186-8","volume":"34","author":"LB Marks","year":"1996","unstructured":"Marks LB (1996) The impact of organ structure on radiation response. Int J Radiat Oncol 34(5):1165\u20131171. https:\/\/doi.org\/10.1016\/0360-3016(95)02186-8","journal-title":"Int J Radiat Oncol"},{"key":"5375_CR19","doi-asserted-by":"publisher","unstructured":"Grass GD et al (2022) Jul., The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. vol. 113, no. 3, pp. 635\u2013647, https:\/\/doi.org\/10.1016\/j.ijrobp.2022.03.006","DOI":"10.1016\/j.ijrobp.2022.03.006"},{"key":"5375_CR20","doi-asserted-by":"publisher","unstructured":"Ulukaya E, Karakas D, Dimas K (Jun. 2021) Tumor chemosensitivity assays are helpful for personalized cytotoxic treatments in Cancer patients. Med (Kaunas) 57(6). https:\/\/doi.org\/10.3390\/medicina57060636","DOI":"10.3390\/medicina57060636"},{"key":"5375_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","volume":"1168","author":"S Morganti","year":"2019","unstructured":"Morganti S, Tarantino P, Ferraro E, D\u2019Amico P, Duso BA, Curigliano G (2019) Next generation sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol 1168:9\u201330. https:\/\/doi.org\/10.1007\/978-3-030-24100-1_2","journal-title":"Adv Exp Med Biol"},{"key":"5375_CR22","doi-asserted-by":"publisher","unstructured":"Pappo AS et al (2003) Feb., Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. vol. 21, no. 4, pp. 638\u2013645, https:\/\/doi.org\/10.1200\/JCO.2003.01.032","DOI":"10.1200\/JCO.2003.01.032"},{"key":"5375_CR23","doi-asserted-by":"publisher","unstructured":"Merks JHM et al (2014) Jan., Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. vol. 25, no. 1, pp. 231\u2013236, https:\/\/doi.org\/10.1093\/annonc\/mdt426","DOI":"10.1093\/annonc\/mdt426"},{"key":"5375_CR24","doi-asserted-by":"publisher","unstructured":"Crist W et al (Mar. 1995) The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol off J Am Soc Clin Oncol 13(3):610\u2013630. https:\/\/doi.org\/10.1200\/JCO.1995.13.3.610","DOI":"10.1200\/JCO.1995.13.3.610"},{"key":"5375_CR25","doi-asserted-by":"publisher","unstructured":"Arndt CAS, Hammond S, Rodeberg D, Qualman S (2006) Significance of persistent mature rhabdomyoblasts in bladder\/prostate rhabdomyosarcoma: Results from IRS IV. J. Pediatr. Hematol. Oncol. vol. 28, no. 9, pp. 563\u2013567, Sep. https:\/\/doi.org\/10.1097\/01.mph.0000212978.21372.97","DOI":"10.1097\/01.mph.0000212978.21372.97"},{"issue":"2","key":"5375_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00043426-200003000-00005","volume":"22","author":"JA Ortega","year":"2000","unstructured":"Ortega JA, Rowland J, Monforte H, Malogolowkin M, Triche T (2000) Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome. J Pediatr Hematol Oncol 22(2):106\u2013111. https:\/\/doi.org\/10.1097\/00043426-200003000-00005","journal-title":"J Pediatr Hematol Oncol"},{"key":"5375_CR27","doi-asserted-by":"publisher","unstructured":"Chisholm J et al (2024) Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers (Basel). vol. 16, no. 5, Feb. https:\/\/doi.org\/10.3390\/cancers16050998","DOI":"10.3390\/cancers16050998"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05375-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:02:09Z","timestamp":1767992529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05375-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5375"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05375-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4953534\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the\n                      Declaration\n                      of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No patients consent was needed for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patients consent"}},{"value":"Yes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}